Rosen Law Firm Urges DexCom Investors to Act Before December Deadline

The Rosen Law Firm, a globally recognized investor‑rights firm, is reminding purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025 (the “Class Period”) that they may be eligible to join a class action, but must act by December 29, 2025 to move the Court and secure lead plaintiff status. According to the lawsuit, DexCom allegedly made unauthorized design changes to its G6 and G7 continuous‑glucose‑monitoring systems, compromising reliability and presenting material health risks. It is claimed the company overstated product enhancements, down‑played the severity of issues, and exposed itself to regulatory and financial fallout — all while making misleading public statements. No upfront fees or costs are required to participate under a contingency‑fee arrangement, says Rosen. Investors who purchased DXCM securities during the Class Period should consider selecting experienced counsel, as many firms simply refer cases rather than litigate them. The Rosen firm emphasizes its track record in leading securities‑class actions and assembling significant recoveries. #DexCom #SecuritiesClassAction #InvestorRights #RosenLawFirm #SlimScan #GrowthStocks #CANSLIM